Posts Archive

NCT04354246: Phase 1: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies COM902 (A TIGIT Inhibitor) in Subjects With...

NCT04674514: Phase 1/2: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple...

NCT04392037: Phase 2: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON) Iberdomide Combined With Low-dose...

IONA-MM NCT04458831: A Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory...

NCT04635735: Phase 1/2: Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma...

NCT04634435: Phase 1/2: Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma...

MCARH109 CART MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma This study will test the...

NCT04497961: Phase 2: A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide...

UNIVERSAL Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma...

NCT04405167: Phase 1: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma NCT04405167: Phase 1: Tasquinimod for the Treatment...

NCT04309981: Phase 1/2: Humanized CART Directed Against BCMA (ARI0002h) in RRMM to Proteasome Inhibitors, Immunomodulators and Anti-CD38...

NCT04613557: Phase 1: Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma...

NCT04508790: Phase 2: Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma...

NCT04244656: Phase 1 -A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma This is a...

NCT04398680: Phase 1: A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function (DREAMM...

NCT04268199: Phase 2: A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment (EASE)...

NCT04246047: Phase 3: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab,...

IsKPd - IFM2018-03 NCT04287855: Phase 2: Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in...

MajesTEC1 study A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1) Relapsed & Refractory...